KC1036
KC1036 is a pharmaceutical drug with 7 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
6
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
A Study of KC1036 in Patients with Advanced Solid Tumors
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Clinical Trials (7)
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
A Study of KC1036 in Patients with Advanced Solid Tumors
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
A Study of KC1036 in Patients with Advanced Thymic Tumors
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
A Food Effect Study of KC1036 in Healthy Subjects
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7